SYRE icon

Spyre Therapeutics
SYRE

Overview Fund Activity

50 hedge funds and large institutions have $19.2M invested in Spyre Therapeutics in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
50
Holders Change
-5
Holders Change %
-9.09%
% of All Funds
0.81%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
12
Reduced
11
Closed
13
Calls
$11K
Puts
–
Net Calls
+$11K
Net Calls Change
+$3K

Top Buyers

1
Millennium Management
1
Millennium Management
New York
$1.41M
2
PVI
2
Pura Vida Investments
New York
$472K
3
Acadian Asset Management
3
Acadian Asset Management
Massachusetts
$625K
4
NCM
4
Nantahala Capital Management
Connecticut
$2.07M
5
SFM
5
Sphera Funds Management
Israel
$198K

Top Sellers

1
PAMS
1
Pictet Asset Management (Switzerland)
Switzerland
$0
2
GPP
2
Great Point Partners
Connecticut
$0
3
SCM
3
Sio Capital Management
New York
$1.35M
4
Goldman Sachs
4
Goldman Sachs
New York
$0
5
BlackRock
5
BlackRock
New York
$291K
Name Holding Trade Value Shares
Change 		Shares
Change %
Goldman Sachs
51
Goldman Sachs
New York
– -$482K -36,628 Closed
Qube Research & Technologies (QRT)
52
Qube Research & Technologies (QRT)
United Kingdom
– -$19K -1,459 Closed
Man Group
53
Man Group
United Kingdom
– -$18K -1,379 Closed
BC
54
BIT Capital
Germany
– -$13.2K -1,000 Closed
LP
55
LMR Partners
United Kingdom
– -$10K -769 Closed
RCM
56
RA Capital Management
Massachusetts
– -$5K -418 Closed
Federated Hermes
57
Federated Hermes
Pennsylvania
– -$1K -77 Closed
Royal Bank of Canada
58
Royal Bank of Canada
Ontario, Canada
– -$1K -56 Closed
1 2
3